Souhaitez-vous accéder aux communiqués récents ?

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Automated Cell Processing System Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Cell Therapy Processing Step, Scale of...

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market by Product, Target, Indication, Demographic, Region, Competitive Landscape - Global Forecast to 2031" has been added to ...

Applied StemCell and Cellipont collaborate to enable seamless iPSC cell therapy development from early engineering to GMP production and scale-up.

RNA Edge combines AI sequence optimization, novel genetic parts, and validation in application-relevant cell models to improve expression and half-life.

BOOST Pharma appoints revered biopharma leader Elaine Jones as Chair, strengthening leadership as BT‑101 advances toward late‑stage development for OI.

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in...

Organoid COMMONS appoints its Governing Board and Alliance Director. Member applications are open through April 30, 2026.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided...